High Neutralizing Antibody Levels Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and BA.2 After UB-612 Vaccine Booster.

The Journal of Infectious Diseases Pub Date : 2022-10-17 DOI:10.1093/infdis/jiac241

Farshad Guirakhoo, Shixia Wang, Chang Yi Wang, Hui Kai Kuo, Wen Jiun Peng, Hope Liu, Lixia Wang, Marina Johnson, Adam Hunt, Mei Mei Hu, Thomas P Monath, Alexander Rumyantsev, David Goldblatt

{"title":"High Neutralizing Antibody Levels Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and BA.2 After UB-612 Vaccine Booster.","authors":"Farshad Guirakhoo, Shixia Wang, Chang Yi Wang, Hui Kai Kuo, Wen Jiun Peng, Hope Liu, Lixia Wang, Marina Johnson, Adam Hunt, Mei Mei Hu, Thomas P Monath, Alexander Rumyantsev, David Goldblatt","doi":"10.1093/infdis/jiac241","DOIUrl":null,"url":null,"abstract":"<p><p>The highly transmissible severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant has caused high rates of breakthrough infections in those previously vaccinated with ancestral strain coronavirus disease 2019 (COVID-19) vaccines. Here, we demonstrate that a booster dose of UB-612 vaccine candidate delivered 7-9 months after primary vaccination increased neutralizing antibody levels by 131-, 61-, and 49-fold against ancestral SARS-CoV-2 and the Omicron BA.1 and BA.2 variants, respectively. Based on the receptor-binding domain protein binding antibody responses, the UB-612 third-dose booster may lead to an estimated approximately 95% efficacy against symptomatic COVID-19 caused by the ancestral strain. Our results support UB-612 as a potential potent booster against current and emerging SARS-CoV-2 variants.</p>","PeriodicalId":509652,"journal":{"name":"The Journal of Infectious Diseases","volume":" ","pages":"1401-1406"},"PeriodicalIF":0.0000,"publicationDate":"2022-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/37/48/jiac241.PMC9278180.pdf","citationCount":"14","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/infdis/jiac241","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 14

Abstract

The highly transmissible severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant has caused high rates of breakthrough infections in those previously vaccinated with ancestral strain coronavirus disease 2019 (COVID-19) vaccines. Here, we demonstrate that a booster dose of UB-612 vaccine candidate delivered 7-9 months after primary vaccination increased neutralizing antibody levels by 131-, 61-, and 49-fold against ancestral SARS-CoV-2 and the Omicron BA.1 and BA.2 variants, respectively. Based on the receptor-binding domain protein binding antibody responses, the UB-612 third-dose booster may lead to an estimated approximately 95% efficacy against symptomatic COVID-19 caused by the ancestral strain. Our results support UB-612 as a potential potent booster against current and emerging SARS-CoV-2 variants.

Abstract Image

查看原文本刊更多论文

UB-612疫苗增强剂抗严重急性呼吸综合征冠状病毒2组粒ba1和ba2的高中和抗体水平

高度传染性的严重急性呼吸综合征冠状病毒2 (SARS-CoV-2)欧米克隆变异在先前接种过2019年祖先株冠状病毒病(COVID-19)疫苗的人群中造成了很高的突破性感染率。在这里，我们证明在初次接种后7-9个月给予UB-612候选疫苗加强剂，分别使针对祖先SARS-CoV-2和Omicron ba - 1和ba -2变体的中和抗体水平提高了131倍、61倍和49倍。基于受体结合域蛋白结合抗体反应，UB-612第三次增强剂对由祖先菌株引起的症状性COVID-19的有效性估计约为95%。我们的研究结果支持UB-612作为对抗当前和新出现的SARS-CoV-2变体的潜在有效增强剂。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

The Journal of Infectious Diseases

自引率

0.00%

发文量